varian report strong result sever metric includ
revenu gross order gross margin ep oncolog gross order
beat consensu estim oncolog revenue
well street forecast non-gaap ep came
cent consensu manag rais revenu
guidanc rang y/i growth lift non-gaap ep guidanc
see metric rel easi hit currenc
ad tailwind sinc last report expect trade higher
thursday feel compani valuat price-to-earnings multipl lofti
maintain neutral rate might look better entri point
conserv revenu goal see fy revenue guidanc bit
conserv sinc includ anticip currenc tailwind
assum currenc stay understand
speed placement vari quarter y/i growth revenue
goe long way toward rang full year
model revenue growth wonder low
oncolog gross order grew y/i quarter strength
emea apac book halcyon hyperarc system
continu roll like meaning proport halcyon
order destin greenfield site open rad onc
gross margin driven superb oncolog gross
margin metric depend product mix neg
impact proton revenu continu expect quarterli
fluctuat tax reset
didnt cash flow guidanc go ask sever time
ep rais seem initi rang wide would
expect upper end hit
valuat rate neutral risk discuss
btig estim compani document million except per share amount
pleas read import disclosur analyst certif appear appendix
varian report total revenu continu oper top
estim consensu expect proton
contribut oncolog system well
estim key metric gross oncolog order came
btig street estim respect varian
also book proton order quarter
gross margin came estim vs
model spend estim sg margin
revenu estim told non-gaap ep
came vs forecast
tweak gross oncolog order slightli increas revenu
forecast go forward strong order result quarter translat
higher revenu futur currenc move varian favor
model y/i total revenu growth near top end guidanc
rang also rais oper expens project slightli ebit
margin forecast within guidanc
increas share count slightli per guidanc lower tax rate
account tax reform non-gaap ep forecast top end
guidanc rang
actualsbtig estimate varianceoncolog revenu revenu revenu incom gross bp sg spend bp spend bp ebit bp tax bpssourc btig estim compani filingsvari
varian rate neutral feel current valuat ntm
ep estim fair expens point larg cap comp
group despit sale ep growth line group stellar quarter
bring valuat bit varian still premium multipl among
compani similar growth btig assign price target neutral-
rate stock risk includ halcyon adopt chang oper margin
capit spend slow hospit govern new
competit healthcar multipl gener trade lumpi quarterli
incom ebit btig estim compani filingsnewold changentm johnsonjnjsel bdxnot scientificbsxbuy factset data btig estimatespr ex-amortcompanytickerr ptpricemarket cap bev/salescagr
varian incom oncolog total y/i good gross sg one-tim total oper incom loss invest incom pre-tax incom incom non- net incom continu net earn discontinu non- dilut share net ex select calendar loss net product product product oper ep ep ep btig estim compani report
varian revenu eoncolog gross america y/i net america order y/i gross emea y/i net emea order y/i gross apac order y/i net apac y/i gross y/i net order y/i trail month gross trail month net y/i contract y/i oncolog y/i gross y/i y/i y/i gross y/i y/i y/i btig estim compani report
btig cover compani mention report
appendix analyst certif import disclosur
